Events Archives - Page 14 of 128

2 minute read

Ascendis Pharma Announces Significant Health And Quality Of Life Improvements Achieved In Children With Achondroplasia Treated For One Year With TransCon CNP At 100 µg/kg/week

December 20, 9:35 AM

TransCon CNP is the first investigational product to demonstrate improvements in health-related quality of life and disease impacts in children with achondroplasia COPENHAGEN, Denmark, Dec. 20, 2023 (GLOBE NEWSWIRE)

ASND

3 minute read

Events

Could Florida Legalize Recreational Cannabis? What You Need To Know When Visiting The Sunshine State

By Abbey Higginbotham

December 19, 3:58 PM

The upcoming Benzinga Cannabis Capital Conference in April 2024 in Hollywood, FL, will discuss the proposed changes to Florida's cannabis laws, from medical to recreational, and how it could open up economic opportunities. Get your tickets now!

TCNNF

2 minute read

Veru To Host Investor Call On January 4th, 2024 To Discuss Recent Financing And Strategy To Prioritize The Development Of Enobosarm As A Combination Treatment To Prevent Muscle Loss And Augment Fat Loss Associated With Weight Loss GLP-1 Drugs

By Benzinga Newsdesk

December 19, 9:42 AM

Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today

VERU

1 minute read

Aldeyra Therapeutics Schedules Conference Call And Webcast On Tuesday, December 19, 2023, At 8:00 a.m. To Announce Top-Line Results From Phase 2 Clinical Trial Of ADX-629 In Patients With Atopic Dermatitis

By Benzinga Newsdesk

December 18, 5:03 PM

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, December 19, 2023, at 8:00 a.m. (ET) to provide top-line results from a Phase 2 clinical trial of

ALDX

1 minute read

Corbus Pharmaceuticals Announces Abstract Accepted For Presentation At 2024 ASCO GU

By Benzinga Newsdesk

December 18, 9:08 AM

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced that the Phase 1, first-in-human clinical data from a dose

CRBP

2 minute read

Blockchain Technology Ushers In New Era Of Digital Connectivity, Gaming, And Finance

By Abbey Higginbotham

December 14, 5:17 PM

Industry leaders at a recent key event unveiled transformative visions for blockchain tech: connectivity, empowerment, and revolutionizing industries.

VOD

3 minute read

BioAtla Hosting Virtual R&D Day To Highlight BA3071 CAB-CTLA-4 Phase 1 Data In Multiple Solid Tumor Types

By Benzinga Newsdesk

December 13, 9:23 AM

Multiple confirmed responses and durable disease control observed Emerging differentiated safety profile enables further exploration at higher dosesOngoing Phase 2 clinical study of monotherapy and in combination

BCAB

2 minute read

Ligand Holds Investor And Analyst Day; Provides Update On Portfolio Progress And Recent Transactions; Introduces 2024 Guidance; Sees FY24 EPS $4.25-$4.75 Vs $4.17 Est.; Revenue $130M-$142M Vs $138.6M Est.

By Benzinga Newsdesk

December 12, 1:06 PM

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) hosted anInvestor and Analyst Day in New York City earlier today. CEO Todd Davis and other members of Ligand's senior management team provided an overview of the

LGND

7 minute read

Syndax Presents Data From Pivotal AUGMENT-101 Trial Of Revumenib In Relapsed/Refractory KMT2Ar Acute Leukemia At Oral Presentation During ASH Meeting; Trial Met Its Primary Endpoint At Interim Analysis Of The Pooled KMT2Ar AML And ALL Cohorts

By Benzinga Newsdesk

December 12, 1:04 PM

– Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); CR/CRh rate consistent across adult and pediatric patients –– 63% overall response

SNDX

4 minute read

Protagonist Reports 2-Year Follow Up Data From Rusfertide REVIVE Study At The ASH Annual Meeting Showing Durable Efficacy And No New Safety Signals

By Benzinga Newsdesk

December 12, 10:08 AM

Long term follow-up from REVIVE Phase 2 study shows durable hematocrit control, decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia veraAnalysis of PACIFIC Phase 2

PTGX